TCRvβ8 chimeric antigen receptor natural killer cells exhibit potent preclinical activity against T-cell malignancies

Lianjun He; Yinmei He; Ye He; Xing Bao; Yuqiong Yang; Xueyi Qian; Ziyun Lin; Weijie He; Yao Wu; Huimin Shao; Lingjie Zhou; Lin Wan; Zhenyu Xu

doi:10.1002/ctm2.70004

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (8) : e70004 DOI: 10.1002/ctm2.70004

LETTER TO THE JOURNAL

TCRvβ8 chimeric antigen receptor natural killer cells exhibit potent preclinical activity against T-cell malignancies

Author information +

History +

PDF

Cite this article

Download citation ▾

Lianjun He, Yinmei He, Ye He, Xing Bao, Yuqiong Yang, Xueyi Qian, Ziyun Lin, Weijie He, Yao Wu, Huimin Shao, Lingjie Zhou, Lin Wan, Zhenyu Xu. TCRvβ8 chimeric antigen receptor natural killer cells exhibit potent preclinical activity against T-cell malignancies. Clinical and Translational Medicine, 2024, 14(8): e70004 DOI:10.1002/ctm2.70004

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms published correction appears in leukemia. Leukemia. 2022;36(7):1720-1748.

[2]	Quist-Paulsen P, Toft N, Heyman M, et al. T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia. 2020;34(2):347-357.

[3]	Fleischer LC, Spencer HT, Raikar SS. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J Hematol Oncol. 2019;12(1):141.

[4]	Dai Z, Mu W, Zhao Y. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transduct Target Ther. 2022;7(1):85.

[5]	Rasaiyaah J, Georgiadis C, Preece R, et al. TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight. 2018;3(13):e99442.

[6]	Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature. 1988;334(6181):395-402.

[7]	Paul S, Pearlman AH, Douglass J, et al. TCR β chain-directed bispecific antibodies for the treatment of T cell cancers. Sci Transl Med. 2021;13(584):eabd3595.

[8]	Li F, Zhang H, Wang W, et al. T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies. Nat Commun. 2022;13(1):4334.

[9]	Shaw LC, Poussin M, Rodriguez-Garcia A, et al. TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones. Blood Adv. 2023;7(9):1885-1898.

[10]	Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520-531.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.